TELO - Telomir Pharmaceuticals, Inc. Common Stock
Telomir Pharmaceuticals, Inc. Common Stock Logo

TELO - Telomir Pharmaceuticals, Inc. Common Stock

https://telomirpharma.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
Telomir Pharma Skyrockets Nearly 139% After-Hours As Cancer Drug Shows Breakthrough Results, Beats Chemo In Human Cell Tests - Telomir Pharmaceuticals ( NASDAQ:TELO )
Benzinga • 1 month, 4 weeks ago • score: 0.53
Telomir Pharmaceuticals Inc TELO experienced an increase of 138.84% in its stock value during after-hours trading on Thursday, noting a regular trading session surge of 5.22% to reach $1.21. What Happened: The surge in stock value followed the announcement of promising data regarding the ...
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company is headquartered in Baltimore, Maryland.

52W High
$8.40
52W Low
$1.12
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
N/A
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
N/A
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
83.18
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
31.50%
Institutions (25–75% balanced)
8.78%
Shares Outstanding
32,281,000
Float
20,136,500
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-0.54
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-15.70%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
-0.0987
Previous
-0.1111
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025